Ulcerative colitis therapy: Importance of delivery mechanisms

Reviews in Gastroenterological Disorders

Volumn 5, Issue 4, 2005, Pages 215-222

  Rochester, Jeremy ^a   Abreu, Maria T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

5 aminosalicylate (5 ASA) agents; Sulfasalazine; Ulcerative colitis

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BALSALAZIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LAXATIVE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

AGRANULOCYTOSIS; ANTIINFLAMMATORY ACTIVITY; BLOOD TOXICITY; CLINICAL TRIAL; CROHN DISEASE; DERMATITIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HEPATITIS; HUMAN; INTERSTITIAL NEPHRITIS; MALE INFERTILITY; META ANALYSIS; MYOCARDITIS; OPEN STUDY; PANCREATITIS; PERICARDITIS; PH MEASUREMENT; PNEUMONIA; PROTEIN FUNCTION; REMISSION; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; TREATMENT OUTCOME;

EID: 29444436828     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Svartz N. Salazopyrin, a New Sulphanilamide Preparation. A. Theraputic results in rheumatic polyarthritis. B. Therapeutic result sulphanilamide colitis. C. Toxic manifestations in treatment with sulphanilamide preparations. Acta Med Scand. 1942;110:577-98.
2. Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980;303(26):1499-1502.
3. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-ammosalicylic acid. Clin Pharmacokinet. 1985;10(4):285-302.
4. Das KM, Eastwood AM, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973; 289(10):491-495.
5. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2(8044):892-895.
6. van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980;21(7):632-635.
7. Haagen Nielsen O, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983;16(6):738-740.
8. Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982;9(2):494-497.
9. Rodenburg RJ, Ganga A, van Lent PL, et al. The andinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum. 2000;43(9):1941-1950.
10. Nikolaus S, Folscn U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology. 2000;47(31): 71-82.
11. Imai F, Suzuki T, Ishibashi T, et al. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. J Rheumatol. 1994; 21(4):612-615.
12. MacDermott RP, Schloemann SR, Bertovich MJ, et al. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989; 96(2 Pt 1):442-448.
13. Aruoma OI, Wasil M, Halliwell B, et al. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem Pharmacol. 1987;36(21):3739-3742.
14. Yan F, Polk DB. Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells. J Biol Chem. 1999;274(51):36631-36636.
15. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin- 1 -stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;274(37):26448-26453.
16. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116(3):602-609.
17. Kennedy M, Wilson L, Szabo C, Salzman AL. 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med. 1999;4(4):437-443.
18. Rogler G, Brand K, Vogl D, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998;115(2):357-369.
19. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101(5): 1163-1174.
20. Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000;95(12):3452-3457.
21. Dew MJ, Ryder RE, Evans N, et al. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. Br J Clin Pharmacol. 1983;16(2):185-187.
22. Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83(5):1062-1070.
23. van Hogezand RA, van Hees PA, Zwanenburg B, et al. Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease. Gastroenterology. 1985;88(3):717-722.
24. Chan RP, Pope DJ, Gilbert AP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983;28(7):609-615.
25. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17(1):29-42.
26. Bondesen S. Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. Pharmacol Toxicol. 1997;81:1-28.
27. Stretch GL, Campbell BJ, Dwarakanath AD, et al. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther. 1996;10(6):941-947.
28. Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004;19(10):1089-1098.
29. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with ammosalicylates and other drugs. Gut. 2001;48(4):571-577.
30. Hebden JM, Blackshaw E, D'Amato M, et al. Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Am J Gastroenterol. 2002;97(9): 2315-2320.
31. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993; 88(8):1188-1197.
32. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-ammosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625-1629.
33. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115(5):350-355.
34. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine 4.8g/day versus 2.4g/day for treatment of moderately active ulcerative colitis: Combined analysis of two randomized double-blind, controlled trials. (abstract). Gastroenterology. 2005;128(4)(suppl 2):74-75.
35. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987;93(6):1255-1262.
36. Study Number CP069101. Data on file at Salix Pharmaceuticals, Inc; Morrisville, NC.
37. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298(6666):82-86.
38. Green JR, Mansfield JC, Gibson JA, et al. A double-blind comparison of balsalazide, 6.75 g daily, and suffasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002; 16(1):61-68.
39. Green JR, Lobo AJ, Holdsworth CD, et al. The Abacus Investigator Group. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology. 1998;114(1):15-22.
40. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002; 97(12):3078-3086.
41. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97(6):ulcerative.
42. Pruitt R, Riff D, Hanson J, et al. Balsalazide as alternative to mesalamine dose-escalation for acute mild-moderate ulcerative colitis. Gastroenterology. 2002;122(A499 (abstract))
43. Kruis W, Brandes JW, Schreiber S, et al. Ol-salazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther. 1998;12(8):707-715.
44. Giaffer MH, O'Brien CJ, Holdsworth CO. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther. 1992;6(1):51-59.
45. Zinberg J, Molinas S, Das KM. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol. 1990;85(5):562-566.
46. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-ammosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 1996;10(6):949-956.
47. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536-539.